Research map: Efficacy of roxadustat for anaemia in kidney transplant recipients and its drug–drug interaction with tacrolimus: A retrospective cohort study

Papers in this map

1. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis · Nan Chen · 2019 · 631 citations · Cited by this paper
2. Relationships among nitrous oxide exposure, neurological injury and biomarkers · 2026 · Related
3. Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis · Nan Chen · 2019 · 588 citations · Cited by this paper
4. Predicting cognitive function in Alzheimer's clinical trials via amyloid β‐protein biomarkers · 2026 · Related
5. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients · Anatole Besarab · 2015 · 288 citations · Cited by this paper
6. Comparative risk of ventricular arrhythmia and sudden cardiac death among acetylcholinesterase inhibitors in dementia: A population‐based cohort study · 2026 · Related
7. The Concise Guide to PHARMACOLOGY 2023/24: Introduction and Other Protein Targets · S P H Alexander · 2023 · 225 citations · Cited by this paper
8. Pharmacogenomics of dolutegravir: A scoping review of evidence, gaps and clinical implications · 2026 · Related
9. Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney Transplantation · Yu Meng · 2018 · 184 citations · Cited by this paper
10. MT‐RNR1 genotype testing for preventing aminoglycoside‐mediated ototoxicity: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx) · 2026 · Related
11. Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study · Steven N. Fishbane · 2021 · 182 citations · Cited by this paper
12. Population pharmacokinetics and pharmacodynamics of canagliflozin in paediatric patients with type 2 diabetes mellitus · 2026 · Related
13. Targeting the HIF pathway in inflammation and immunity · Carsten C. Scholz · 2013 · 157 citations · Cited by this paper
14. Trends in publicly subsidized and private access to GLP‐1 medicines indicated for type 2 diabetes in Australia, 2020–2025 · 2026 · Related
15. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES) · Jonathan Barratt · 2021 · 150 citations · Cited by this paper
16. Analysis of spontaneous reports of suspected adverse reactions related to medical cannabis from the Italian Phytovigilance System · 2026 · Related
17. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury · Yunwen Yang · 2018 · 125 citations · Cited by this paper
18. A university‐certified course on dossier assessment for regulatory scientists in Africa—Reporting on our 5‐year experience · 2026 · Related
19. Posttransplantation Anemia in Adult Renal Allograft Recipients: Prevalence and Predictors · Nilesh Shah · 2006 · 123 citations · Cited by this paper
20. Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease · Joshua M. Kaplan · 2018 · 105 citations · Cited by this paper
21. A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study · Chaim Charytan · 2021 · 104 citations · Cited by this paper
22. Treatment of Renal Anemia with Roxadustat: Advantages and Achievement · Zuo‐Lin Li · 2020 · 84 citations · Cited by this paper
23. Sirolimus Interferes with Iron Homeostasis in Renal Transplant Recipients · Annamaria Maiorano · 2006 · 77 citations · Cited by this paper
24. Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks · Iain C. Macdougall · 2005 · 77 citations · Cited by this paper
25. Phase 3 Study of Roxadustat to Treat Anemia in Non–Dialysis-Dependant CKD · Tadao Akizawa · 2021 · 69 citations · Cited by this paper
26. Roxadustat treatment for anemia in peritoneal dialysis patients: A randomized controlled trial · Yanpei Hou · 2021 · 68 citations · Cited by this paper
27. Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation · David James Taber · 2017 · 67 citations · Cited by this paper
28. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against renal ischemia/reperfusion injury by inhibiting inflammation · A-Feng Miao · 2021 · 62 citations · Cited by this paper
29. Anemia After Kidney Transplantation · Yves F. Ch. Vanrenterghem · 2009 · 61 citations · Cited by this paper
30. Review of two immunosuppressants: tacrolimus and cyclosporine · HyunJong Lee · 2023 · 60 citations · Cited by this paper
31. Roxadustat: Not just for anemia · Xiaoyu Zhu · 2022 · 56 citations · Cited by this paper
32. How I treat renal anemia · Steven N. Fishbane · 2020 · 42 citations · Cited by this paper
33. Posttransplantation anemia in kidney transplant recipients · Anat Gafter‐Gvili · 2017 · 39 citations · Cited by this paper
34. Transcriptional regulation of CYP3A4 by nuclear receptors in human hepatocytes under hypoxia · Xuechun Yuan · 2020 · 24 citations · Cited by this paper
35. Treating Posttransplant Anemia With Erythropoietin Improves Quality of Life but Does Not Affect Progression of Chronic Kidney Disease · Taryn Pile · 2019 · 21 citations · Cited by this paper
36. Downregulation of CYP1A2, CYP2B6, and CYP3A4 in Human Hepatocytes by Prolyl Hydroxylase Domain 2 Inhibitors via Hypoxia-Inducible Factor-α Stabilization · Hiroki Takano · 2020 · 21 citations · Cited by this paper
37. Therapeutic Effect of Roxadustat on Patients With Posttransplant Anemia · Katsuyuki Miki · 2022 · 20 citations · Cited by this paper
38. Roxadustat: Do we know all the answers? · Qiuyu Li · 2023 · 20 citations · Cited by this paper
39. Post renal transplant pure red cell aplasia—is tacrolimus a culprit? · Malagouda R. Patil · 2016 · 19 citations · Cited by this paper

Source: OpenAlex (CC0)